Tumor burden assessment with positron emission tomography with [18-F] 2-fluoro 2-deoxyglucose (FDG PET) modeled in metastatic renal cell cancer Journal Article
| Authors: | Akhurst, T.; Ng, V.; Larson, S. M.; O'Donoghue, J. A.; O'Neel, J.; Erdi, Y.; Divgi, C. R. |
| Article Title: | Tumor burden assessment with positron emission tomography with [18-F] 2-fluoro 2-deoxyglucose (FDG PET) modeled in metastatic renal cell cancer |
| Abstract: | Objective: In patients with advanced cancer, total tumor burden affects the likelihood of tumor response and has important implications for prognosis. The aim of this study was to select the optimum 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG PET) tumor uptake parameter to accurately measure tumor burden in advanced metastatic renal cell cancer, in comparison with volumes measured with computed tomography (CT), as a reference test. Materials and Methods: Six patients with metastatic renal cell carcinoma measurable on CT were studied. CT and FDG PET scans were carried out on all patients within 4 weeks prior to their entry into a phase I-II radioimmunotherapy trial. CT-based evaluation of disease extent (tumor volume) and 4 PET-based measurements (standardized uptake value[SUVmax], SUVav, volume, and total lesion glycolysis [TLG]) were performed independently by a radiologist (VN) and a nuclear medicine physician (TA). The degree of correlation between conventional (CT) extent of disease and parameters describing tumor concentration of FDG was then determined. Results: Fifty-seven CT-measurable metastatic lesions in lung, abdomen, and scalp were evaluated in 6 patients. There was a high correlation between CT and FDG PET volume estimates for lesions greater than 5 cm3 in size. However, a PET-derived parameter that embodies both FDG uptake and lesion size, the TLG, correlated better with CT-derived tumor volume than did FDG PET volume alone. Conclusion: Using CT volume as a gold standard, the optimal PET-based estimate of total tumor burden in patients with metastatic renal cancer is the sum over all lesions of the total lesion glycolysis. Copyright © 2000 Elsevier Science Inc. All rights reserved. |
| Keywords: | positron emission tomography; renal cell cancer; pet; fluorodeoxyglucose; fdg; suv; tlg; tumor burden assessment |
| Journal Title: | Clinical Positron Imaging |
| Volume: | 3 |
| Issue: | 2 |
| ISSN: | 1095-0397 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2000-03-01 |
| Start Page: | 57 |
| End Page: | 65 |
| Language: | English |
| DOI: | 10.1016/s1095-0397(00)00041-8 |
| PROVIDER: | scopus |
| PUBMED: | 10838401 |
| DOI/URL: | |
| Notes: | Export Date: 18 November 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work